MAIA Biotechnology, Inc. (MAIA) Investor Relations Documents

MAIA Biotechnology, Inc. (MAIA) investor relations documents from the company's IR site: 1 presentation, 22 press releases. Read in-app with summaries. First-party data.

Corporate Presentation: MAIA Biotechnology is developing Ateganosine (THIO), a telomere-targeting immunotherapy, currently in Phase 3 and Phase 2 trials for NSCLC and other cancers.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-08Press releaseMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 P
2026-06-25Press releaseJun 25, 2026 • 8:08am EDT MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion
2026-06-18Press releaseJun 18, 2026 • 8:30am EDT MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Ag
2026-06-10Press releaseJun 10, 2026 • 9:15am EDT MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for Internation
2026-06-04Press releaseMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
2026-06-03Press releaseMAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
2026-06-02Press releaseMAIA Biotechnology Announces Open Market Purchases by CEO and Director
2026-06-01Press releaseMAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agen
2026-04-16Press releaseMAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeti
2026-04-16Press releaseDownload as PDF
2026-04-08Press releaseMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomer
2026-04-08Press releaseDownload as PDF
2026-03-31Press releaseDownload as PDF
2026-03-04Press releaseDownload as PDF
Press releaseMAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
Press releaseMAIA Biotechnology to Present at Two Investor Conferences in April 2024
Press releaseMAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
Press releaseMAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Press releaseMAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Press releaseMAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticance
Press releaseMAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non
Press releaseMAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
PresentationCorporate Presentation

MAIA overview · MAIA earnings · MAIA financials · MAIA KPIs · MAIA ownership · MAIA peers · MAIA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.